Cerep Signs Deal with Sanofi-Aventis

Contract pharmaceutical ingredients manufacturer and pharmaceutical developer Cerep (Paris) says it has signed a drug license agreement with Sanofi-Aventis. The agreement relates to a drug for treating diabetes that was co-developed by the two companies. The drug is currently in pre-clinical trials. The licensing agreement triggers a milestone...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers